Outcome of the largest cohort of patients with FA who underwent transplantation from a matched related donor
| Reference . | Patients (n) . | Prevalently using conditioning . | Follow-up . | aGVHD . | cGVHD . | TRM/NRM . | OS . | Malignancies, No. (%) . |
|---|---|---|---|---|---|---|---|---|
| Pasquini et al45 (2008) | 148 | Cy ± ATG ± Bus TAI, TLI, TBI + Cy ± ATG | 5 years (censored) | 19% (grades II-IV) | 20% at 5 years | 17.5% (overall) | 78% (IRR) 81% (no IRR) | 4/148 (2.7%) |
| Peffault de Latour et al26 (2013) | 211 (post 1999) | Flu + ATG ± IRR | 6 years | 36% (grades III-IV) | 20% at 5 years | 14% | 76% at 5 years | 15-year CI 15% overall |
| Benajiba et al46 (2015) | 20 | Flu + Cy | 2 years | 15% (grades III-IV) | 10% extensive 15% limited | 5% | 95% at 2 years | 0 |
| Bonfim et al47 (2019) | 91 | Cy + ATG | 3-7 years | 11% (grades II-IIV) | 23.5% | 7% | 95% at 5 years | 1/43 (2.3%) |
| Bernard et al48 (2021) | 42 | Flu-Cy-alemtuzumab | 74.4 months | 6.1% (grades II-IV) overall | 2.4% overall | 13.8% overall | 85.4% at 5 years | 3/82 (3.6%) overall |
| Modified from Pierri et al.13 | ||||||||
| ATG, antithymocyte globulin; Bus, busulfan; Cy, cyclophosphamide; Flu, fludarabine; IRR, irradiation in conditioning regimen; NR, not reported; TAI, thoraco-abdominal irradiation; TBI, total body irradiation; TLI, total lymph node irradiation; TRM/NRM, transplant-related mortality/nonrelapse mortality. | ||||||||
| Reference . | Patients (n) . | Prevalently using conditioning . | Follow-up . | aGVHD . | cGVHD . | TRM/NRM . | OS . | Malignancies, No. (%) . |
|---|---|---|---|---|---|---|---|---|
| Pasquini et al45 (2008) | 148 | Cy ± ATG ± Bus TAI, TLI, TBI + Cy ± ATG | 5 years (censored) | 19% (grades II-IV) | 20% at 5 years | 17.5% (overall) | 78% (IRR) 81% (no IRR) | 4/148 (2.7%) |
| Peffault de Latour et al26 (2013) | 211 (post 1999) | Flu + ATG ± IRR | 6 years | 36% (grades III-IV) | 20% at 5 years | 14% | 76% at 5 years | 15-year CI 15% overall |
| Benajiba et al46 (2015) | 20 | Flu + Cy | 2 years | 15% (grades III-IV) | 10% extensive 15% limited | 5% | 95% at 2 years | 0 |
| Bonfim et al47 (2019) | 91 | Cy + ATG | 3-7 years | 11% (grades II-IIV) | 23.5% | 7% | 95% at 5 years | 1/43 (2.3%) |
| Bernard et al48 (2021) | 42 | Flu-Cy-alemtuzumab | 74.4 months | 6.1% (grades II-IV) overall | 2.4% overall | 13.8% overall | 85.4% at 5 years | 3/82 (3.6%) overall |
| Modified from Pierri et al.13 | ||||||||
| ATG, antithymocyte globulin; Bus, busulfan; Cy, cyclophosphamide; Flu, fludarabine; IRR, irradiation in conditioning regimen; NR, not reported; TAI, thoraco-abdominal irradiation; TBI, total body irradiation; TLI, total lymph node irradiation; TRM/NRM, transplant-related mortality/nonrelapse mortality. | ||||||||